CareDx SHORE Study Shows HeartCare Test Triples Risk Prediction for Heart Transplant Patients
CareDx Inc. published results from the SHORE study in the Journal of Heart and Lung Transplantation, showing that their HeartCare test significantly increases risk prediction for heart transplant patients. The study analyzed 1,934 patients and found positive HeartCare results linked to higher risks of graft dysfunction and cardiovascular death, even with normal biopsy results. This highlights the test's prognostic value in heart transplant recipients.
CareDx Inc. announced the publication of results from the Surveillance HeartCare Outcomes Registry (SHORE) in the Journal of Heart and Lung Transplantation. The study evaluated the prognostic value of the HeartCare platform, which integrates AlloMap and AlloSure Heart molecular tests, in heart transplant recipients. Findings from the analysis of 1,934 patients across 59 centers indicate that positive HeartCare results are associated with a higher risk of graft dysfunction and cardiovascular death, even when biopsy results appear normal. The results have been published and are available in the referenced journal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124482007) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
